Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
BioNTech's breast cancer drug meets its Phase 3 endpoint but serious lung toxicity raises concerns. Explore the results and approval outlook.
Pharma & Biotech
Pharma & Biotech
Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment?
Natera reports 91% two-year event-free survival in persistently ctDNA-negative VOLGA patients, strengthening MRD research in bladder cancer.
Pharma & Biotech
Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use?
Enhertu wins EU approval after cutting invasive recurrence or death risk by 53% versus T-DM1. Lung toxicity remains a key consideration.
Pharma & Biotech
AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen?
AstraZeneca's VOLGA trial shows 42% lower death risk with IMFINZI and enfortumab vedotin. Can the regimen compete with approved bladder cancer therapy?
Features & Analysis
AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24
Pharma & Biotech
Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Roche and Ionis report a 43.1% Phase 3 proteinuria reduction with sefaxersen. Two-year kidney function results remain the next major test.
Pharma & Biotech
Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?
Innate Pharma plans its November 5 update as IPH4502 data, the Sobi partnership and monalizumab milestones approach. Key clinical questions remain.
Pharma & Biotech
What does RC220 dose escalation mean for Racura Oncology’s cancer drug pipeline?
Racura Oncology clears RC220 dose escalation to 100 mg/m² in its lung cancer trial. Examine the safety findings and next clinical milestones.
Pharma & Biotech
Can Lunit’s AI pathology partnership accelerate cancer biomarker discovery?
Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.
Medical Devices & Diagnostics
How Guardant360 CDx detects ESR1 mutations before breast cancer progresses on imaging
Guardant360 CDx gains European CE marking for ETCAMAH patient selection. See how ESR1 blood testing changes advanced breast cancer treatment.